［1］Venook AP，Niedzwiecki D，Lenz HJ，et al.Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer：A randomized clinical trial［J］.JAMA，2017，317(23)：2392-2401.
[2]Xu R，Xu C，Liu C，et al.Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer［J］.Onco Targets Ther，2018（11）：8605-8621.
[3]Holch JW，Ricard I，Stintzing S，et al.Relevance of baseline carcinoembryonic antigen for first-line treatment against metastaticcolorectal cancer with FOLFIRI plus cetuximab or bevacizumab(FIRE-3 trial)［J］.Eur J Cancer，2019（106）：115-125.
[4]Goldstein DA，Chen Q，Ayer T，et al.First-and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer：A United States-based cost-effectiveness analysis［J］.J Clin Oncol，2015，33(10)：1112-1118.
[5]Matsuda C，Honda M，Tanaka C，et al.A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer：The AIRS study［J］.Cancer Chemother Pharmacol，2018，81(6)：1035-1041.
[6]Miyamoto Y，Tsuji A，Tanioka H，et al.Correction to：S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer：A multicenter phase II study in Japan (KSCC1102)［J］.Int J Clin Oncol，2018，23(2)：402.
[7]Gonzalez EC，RoetzlIeim RG，Ferrante JM，et al.Predictors of proximal vs distal colorectal cancers［J］.Dis Colon Rectum，2001，44(24)：251-258.
[8]Bendardaf R，Buhmeida A，Hilska M，et al.VEGF-1 expression in colorectal cancer is associated with disease localization，stage，and long-term disease-specific survival［J］.Anticancer Res，2008，28(6B)：3865-3870.
[9]Giantonio BJ，Catalano PJ，Meropol NJ，et al.Bevacizumab in combination with oxaliplatin，fluorouracil，and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer：Results from the eastern cooperative oncology group study E3200［J］.J Clin Oncol，2007，25(12)：1539-1544.
[10]Hurwitz H，Fehrenbacher L，Novotny W，et al.Bevacizumab plus irinotecan，fluorouracil，and leucovorin for metastatic colorectal cancer［J］.N Engl J Med，2004，350(23)：2335-2342.
[11]QIN SK，DENG YH，BI F，et al.Efficacy and safety of bevacizumab in combination with fluoropyrimidine-based chemotherapy for the treatment of advanced metastatic colorectal cancer：A prospective，non-intervention and post-marketing multicenter clinical study(REACT)［J］.Chin Clin Oncol，2016，21(10)：865-873.［秦叔逵，邓艳红，毕锋，等.贝伐珠单抗联合含氟尿嘧啶类化疗方案治疗晚期转移性结直肠癌的前瞻性、非干预性、全国多中心临床研究(REACT)［J］.临床肿瘤学杂志，2016，21(10)：865-873.］
[12]Takahashi S．Vascular endothelial growth factor (VEGF)，VEGF receptors and their inhibitors for antiangiogenic tumor therapy［J］.Biol Pharm Bull，2011，34(12)：1785-1788.
[13]Cohen MH，Gootenberg J，Keegan P，et al.FDA drug approval summary：bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer［J］.Oncologist，2007，12(3)：356-361.
[14]Benedix F，Kube R，Meyer F，et al.Comparison of 17641 patients with right-and left-sided colon cancer：Differences in epidemiology，perioperative course，histology，and survival［J］.Dis Colon Rectum，2010，53(1)：57-64.
[15]Nawa T，Kato J，Kawamoto H，et al.Differences between right and left-sided colon cancer in patient characteristics，cancer morphology and histology［J］.J Gastroenterol Hepatol，2008，23(3)：418-423.
[16]LI Xiaoxue，LOU Changjie，LU Haibo.Biological differences and prognosis of left- and right-sided colon cancers［J］.Modern Oncology，2017，25(09)：1508-1512.［李晓雪，娄长杰，陆海波.左右半结肠癌生物学差异及生存预后［J］.现代肿瘤医学，2017，25(09)：1508-1512.］
[17]Boisen MK，Johansen JS，Dehlendorff C，et al.Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer［J］.Ann Oncol，2013，24(10)：2554-2559.
[18]Loupakis F，Hurwitz HI，Saltz L，et al.Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer［J］.Br J Cancer，2018，119(12)：1451-1455.
[19]Berger MD，Lenz HJ.The safety of monoclonal antibodies for treatment of colorectal cancer［J］.Expert Opin Drug Saf，2016，15(6)：799-808.